Arcadia Biosciences Names Veteran CPG Leader Laura Pitlik Chief Marketing Officer
Accomplished Packaged Goods Marketer Will Lead Product Launch and Brand Execution for Consumer Nutrition, Health and Wellness Portfolio
DAVIS, Calif. (July 20, 2021) – Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has named Laura Pitlik its chief marketing officer, as the company expands its consumer goods platforms following several key acquisitions.
A veteran consumer packaged goods strategist, Pitlik will spearhead brand development and omnichannel marketing activities for Arcadia’s portfolio of consumer nutrition, health and wellness brands, including GoodWheat™, Soul Spring™, ProVault™, Saavy Naturals™ and Zola® coconut water. She will also lead the company’s go-to-market strategies for the e-commerce, retail and food service channels.
“Having significantly expanded our portfolio of plant-based, better-for-you food and wellness products, Arcadia is now exceptionally well-positioned to accelerate our transition to a dynamic consumer products company in on-trend categories with significant growth potential,” said Matt Plavan, Arcadia CEO. “Laura is the right marketing leader at just the right time. With a proven track record of building numerous popular food and beverage brands in fast-paced, competitively demanding environments, she is well-equipped to guide our go-to-market strategies and establish the GoodWheat and Lief Brands portfolios of products as international household name brands – raising the bar on global health.”
“Arcadia is at an exciting inflection point, with a tremendous opportunity to leverage its origins in scientific discovery to now lead the way through seed-to-table innovation in foods that have superior taste and greater intrinsic nutrition with GoodWheat. Additionally, Arcadia’s innovative Lief Brands portfolio directly addresses consumers’ evolving and increasingly sophisticated wellness needs with unique, quality products,” said Pitlik. “I am thrilled to be joining this outstanding, forward-looking team as the company embarks on a transformational phase of growth.”
An accomplished marketing executive, Pitlik’s experience developing new products and brands began early in her career when she led the launch of Dr Pepper® Cherry and continued when she launched the first national line of all-natural breads, Nature’s Pride®, for Hostess Brands. Since then, she has continued to build deep expertise in the consumer packaged goods industry, leading brands including Wonder® Bread and On The Border® tortilla chips and salsas.
With roots in breakthrough agricultural biotechnology, Arcadia has invested more than $250 million to develop a patented trait portfolio that has successfully increased the productivity and nutrition of key global crops and is now primed for commercialization. Since the introduction in 2018 of its GoodWheat portfolio of specialty wheat ingredients with intrinsically strong nutritional profiles, Arcadia has been transitioning its focus to leveraging its technologies to innovate new plant-based food and wellness products.
About Arcadia Biosciences, Inc.
With origins as a trailblazing developer of science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, Arcadia Biosciences (Nasdaq: RKDA) is now a producer of innovative, plant-based health and wellness products, within the portfolios of GoodWheat™ and Lief™, which includes popular brands Soul Spring™, ProVault™, Saavy Naturals™ and Zola® coconut water. The company’s growing number of innovative offerings are designed to enhance quality and health benefits in an array of consumer product categories. For more information, visit www.arcadiabio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding sales growth and product awareness and innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: Arcadia’s and its partners’ and affiliates’ ability to develop commercial products incorporating their traits, and complete the regulatory review process for such products; customer demand and commercial success of such products; Arcadia’s compliance with laws and regulations that impact Arcadia’s business, including the sale of products containing CBD, and changes to such laws and regulations; Arcadia’s future capital requirements and ability to satisfy its capital needs; Arcadia’s ability to develop, enforce and defend its intellectual property rights; and the other risks set forth in Arcadia’s filings with the Securities and Exchange Commission from time to time, including the risks set forth in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2020 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.
Arcadia Biosciences Contacts:
Marie Espinel or Hannah Arnold
The LAKPR Group
firstname.lastname@example.org or email@example.com
Chief Financial Officer
LinkedIn: Arcadia Biosciences